Harmony Biosciences Holdings (HRMY) Change in Receivables (2020 - 2026)

Harmony Biosciences Holdings has disclosed Change in Receivables across 7 years of filings, most recently posting $11.4 million for Q1 2026.

• Change in Receivables for Q1 2026 came in at $11.4 million, down 50.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 million (down 91.42% YoY), and the FY2025 annual result was $13.8 million, up 54.66% from the prior year.
• Change in Receivables came in at $11.4 million for Q1 2026 at Harmony Biosciences Holdings, up from -$3.9 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $22.9 million in Q1 2025 to a low of -$13.0 million in Q2 2025.
• The 5-year median for Change in Receivables is $3.5 million (2023), against an average of $4.3 million.
• Across the five-year window, Change in Receivables soared 2215.69% in 2023 and plunged 477.78% in 2025, its largest moves.
• Harmony Biosciences Holdings' Change in Receivables stood at -$325000.0 in 2022, then jumped by 2215.69% to $6.9 million in 2023, then slumped by 77.73% to $1.5 million in 2024, then tumbled by 352.38% to -$3.9 million in 2025, then jumped by 395.94% to $11.4 million in 2026.
• The last three Change in Receivables figures came in at $11.4 million (Q1 2026), -$3.9 million (Q4 2025), and $7.7 million (Q3 2025), per Business Quant data.